| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4289291 | International Journal of Surgery Case Reports | 2014 | 5 Pages |
•Only early diagnosis and resection are factors that can prolong patient survival.•Physician's suspicion and early detection are crucial to increase resecability of SBA.•Multi institutional cooperation is essential because of the rarity of this tumor.
INTRODUCTIONAdenocarcinoma of the small intestine is a rare malignancy (the annual incidence in the USA is approximately 3.9 cases per million persons with median age between 60 and 70 years) with limited data available to guide therapeutic decisions. Nonspecific signs and symptoms associated with difficulty in performing small bowel examination is the cause of delayed diagnosis made between 6 and 9 months after appearance of symptoms with the majority of patients presenting with late stage disease and either lymph node involvement or distant metastatic disease.PRESENTATION OF CASEAn 87-year-old man treated 3 years previously for colonic adenocarcinoma with left colectomy, was brought to our attention with a 4.5 cm × 3.5 cm mass in the proximal jejunum associated with another abdominal wall enhancing mass of 5 cm in diameter in the rectus muscle. Diagnosis on gross examination after surgical resection was adenocarcinoma stage III (T4N1M0) with involvement of lymph nodes.DISCUSSIONAccording to an analysis of the Surveillance, Epidemiology and End Results (SEER) database, patients who develop either a small or large intestine adenocarcinoma are at increased risk for a second cancer at both intestinal sites. The role of adjuvant therapy in patients who undergo curative resection is unclear. Recent retrospective and prospective studies have helped to clarify the optimal chemotherapy approach for advanced small bowel adenocarcinoma.CONCLUSIONWith our work, we present our personal case of metachronous primary carcinoma of small bowel following resected colorectal carcinoma and review the literature.
